Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

Mostrar otras versiones (1)

BACKGROUND: Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor shown to improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma patients at high risk of recurrence. PATIENTS AND METHODS: Patients with resecte...

Descripción completa

Detalles Bibliográficos
Autores principales: Corrie, P G, Marshall, A, Nathan, P D, Lorigan, P, Gore, M, Tahir, S, Faust, G, Kelly, C G, Marples, M, Danson, S J, Marshall, E, Houston, S J, Board, R E, Waterston, A M, Nobes, J P, Harries, M, Kumar, S, Goodman, A, Dalgleish, A, Martin-Clavijo, A, Westwell, S, Casasola, R, Chao, D, Maraveyas, A, Patel, P M, Ottensmeier, C H, Farrugia, D, Humphreys, A, Eccles, B, Young, G, Barker, E O, Harman, C, Weiss, M, Myers, K A, Chhabra, A, Rodwell, S H, Dunn, J A, Middleton, M R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096737/
https://www.ncbi.nlm.nih.gov/pubmed/30010756
http://dx.doi.org/10.1093/annonc/mdy229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096737/
https://www.ncbi.nlm.nih.gov/pubmed/30010756
http://dx.doi.org/10.1093/annonc/mdy229

Ejemplares similares